FCF YoY
-9.00%
OCF YoY
-7.02%
Capex YoY
+14.22%
FCF Conversion Δ
-2 pp
Free cash flow bridge for Bristol-Myers Squibb (BMY) — TTM through Q1 2026 vs TTM through Q1 2025
Δ Free cash flow: −$1.18B
FCF bridge breakdown for Bristol-Myers Squibb (BMY) — TTM through Q1 2026 vs TTM through Q1 2025
| Driver | Contribution | % of Δ |
|---|---|---|
| Prior Free Cash Flow | $13.09B | — |
| Operating Cash Flow | −$1.00B | -85.2% |
| Capital Expenditure | −$174.00M | -14.8% |
| Free Cash Flow | $11.91B | — |
- Prior Free Cash Flow$13.09B
- Operating Cash Flow−$1.00B
- Capital Expenditure−$174.00M
- Free Cash Flow$11.91B
Identity check: drivers reconcile to ΔNI within $0.00 ✓
Want to see how cash flow is built up?Cash Flow Waterfall
Frequently asked questions
Data & methodology
Bristol-Myers Squibb (BMY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement